Associated Papers
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
Dominant-Negative Effects of p53 R337 Variants in Li-Fraumeni Syndrome: Impact on Tetramer Formation and Transcriptional Activity.
Kamada R et al.
Chembiochem : a European Journal of Chemical Biology, 2025
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
Investigation of the impact of R273H and R273C mutations on the DNA binding domain of P53 protein through molecular dynamic simulation.
R HC et al.
Journal of Biomolecular Structure & Dynamics, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
Huang Y et al.
European Journal of Medicinal Chemistry, 2024
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).
Degtjarik O et al.
Nature Communications, 2021
p53 Forms Redox-Dependent Protein-Protein Interactions through Cysteine 277.
Shi T et al.
Antioxidants (basel, Switzerland), 2021
The disordered DNA-binding domain of p53 is indispensable for forming an encounter complex to and jumping along DNA.
Graha Subekti DR et al.
Biochemical and Biophysical Research Communications, 2021
Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments.
de Bakker T et al.
Frontiers in Oncology, 2021
Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains.
Kamagata K et al.
Scientific Reports, 2020
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
Zhang Q et al.
Cell Death & Disease, 2018
The Disordered Linker in p53 Participates in Nonspecific Binding to and One-Dimensional Sliding along DNA Revealed by Single-Molecule Fluorescence Measurements.
Subekti DRG et al.
Biochemistry, 2017
Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB et al.
Plos One, 2016
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
15-Deoxy-Delta(12,14)-prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue.
Kim DH et al.
Oncogene, 2010